Novo Nordisk Group - NVO Net earnings per share (EPS TTM)

Official company branding of Novo Nordisk (NVO)

Novo Nordisk A/S (NVO) dominance in diabetes and obesity therapy provides the company with powerful pricing power. The company's rolling annual profit per unit clearly demonstrates this resilience, where the value of 3.96 corresponds to the current metric. Profit growth is based on scaling production amid high demand, despite the costs of establishing global climate logistics for the safe delivery of medications.

NVO (Novo Nordisk A/S) Net earnings per share for the last four quarters history from 07/04/2022 to 11/18/2026

Analytical breakdowns for Novo Nordisk A/S

- current quotes and average value forecast:
Fundamental valuation:NVO - Novo Nordisk Group
Manufactured products of Novo Nordisk Inc.

The 12-month earnings per share reflects the equity income derived by dividing the company's total profit by its number of outstanding shares, allowing for an assessment of real business efficiency regardless of capital structure. By analyzing the annual earnings per share, an investor can see how the record investments of Novo Nordisk A/S (NVO) into the development of oral semaglutide forms and innovations in diabetes therapy convert into actual profit growth.